World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
101
Citations
46652
World Ranking
7861
National Ranking
770

David Oscier publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where David Oscier sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 499 publications — 58th percentile

58% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

David Oscier D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where David Oscier sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 101 D-Index — 61st percentile

61% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

David Oscier is affiliated with the Royal Bournemouth Hospital in the United Kingdom and focuses primarily on medical research. Their work spans several interconnected fields, with a concentration on genetics, pathology and forensic medicine, immunology, oncology, and pulmonary and respiratory medicine.

The main topics covered in their research include chronic lymphocytic leukemia research, lymphoma diagnosis and treatment, immunodeficiency and autoimmune disorders, advanced breast cancer therapies, genomic variations and chromosomal abnormalities, cancer genomics and diagnostics, and monoclonal and polyclonal antibodies research.

Throughout their career, David Oscier has contributed to a significant number of publications, frequently appearing in well-regarded venues such as Blood, Leukemia, HemaSphere, Haematologica, and Cancers. The following are some recent papers authored or co-authored by them:

  • Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL, 2020, Blood
  • Genetic and phenotypic attributes of splenic marginal zone lymphoma, 2021, Blood
  • Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multi-center study, 2020, Haematologica
  • Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial, 2020, Leukemia
  • Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY, 2022, Leukemia

Collaboration has been an important aspect of their work, with frequent co-authors including:

  • Zadie Davis
  • Κώστας Σταματόπουλος
  • Paolo Ghia
  • Jonathan C. Strefford
  • Lydia Scarfò

David Oscier's research contributes to better understanding of hematological malignancies, particularly chronic lymphocytic leukemia and related lymphomas. Their focus on genetic and phenotypic attributes aids in refining disease classification and prognosis.

Best Publications

  • International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes

    Peter Greenberg;Christopher Cox;Michelle M. LeBeau;Pierre Fenaux

  • Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.

    Terry J. Hamblin;Zadie Davis;Zadie Davis;Anne Gardiner;Anne Gardiner;David G. Oscier;David G. Oscier

  • Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

    Thomas Ernst;Andrew J Chase;Andrew J Chase;Joannah Score;Joannah Score;Claire E Hidalgo-Curtis;Claire E Hidalgo-Curtis

  • Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders

    Amy V. Jones;Sebastian Kreil;Katerina Zoi;Katherine Waghorn

  • ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile

    Adrian Wiestner;Andreas Rosenwald;Todd S. Barry;George Wright

  • CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease.

    Terry J. Hamblin;Jenny A. Orchard;Rachel E. Ibbotson;Zadie Davis

  • Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

    D Catovsky;S Richards;E Matutes;D Oscier

  • Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities.

    Gunnar Juliusson;David G. Oscier;Margaret Fitchett;Fiona M. Ross

  • ZAP-70 expression and prognosis in chronic lymphocytic leukaemia

    Jenny A Orchard;Rachel E Ibbotson;Zadie Davis;Adrian Wiestner

  • Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation

    Giulia Fabbri;Silvia Rasi;Davide Rossi;Vladimir A. Trifonov

  • Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors.

    David G. Oscier;Anne C. Gardiner;Sarah J. Mould;Sharron Glide

  • Myelodysplastic syndromes: a scoring system with prognostic significance

    G. J. Mufti;J. R. Stevens;D. G. Oscier;T. J. Hamblin

  • Eradication of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia After Alemtuzumab Therapy Is Associated With Prolonged Survival

    Paul Moreton;Ben Kennedy;Guy Lucas;Michael Leach

  • Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies

    Andreas Agathangelidis;Nikos Darzentas;Anastasia Hadzidimitriou;Xavier Brochet

  • JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms.

    Amy V Jones;Andrew Chase;Richard T Silver;David Oscier

  • Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis

    Mary F. McMullin;D. Bareford;P. Campbell;A. R. Green

  • Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms.

    Francis H. Grand;Claire E. Hidalgo-Curtis;Thomas Ernst;Katerina Zoi

  • Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes.

    David Bowen;Dominic Culligan;Simon Jowitt;Stephen Kelsey

  • The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo

    Victoria J. Weston;Ceri E. Oldreive;Anna Skowronska;David G. Oscier

  • Inactivating mutations of the histone methyltransferase EZH2 in myeloid disorders

    T Ernst;A Chase;J Score;C Hidalgo-Curtis

Frequent Co-Authors

Richard Rosenquist
Richard Rosenquist Karolinska Institute
Paolo Ghia
Paolo Ghia Vita-Salute San Raffaele University
Kostas Stamatopoulos
Kostas Stamatopoulos Centre for Research and Technology Hellas
Šárka Pospíšilová
Šárka Pospíšilová Masaryk University
Daniel Catovsky
Daniel Catovsky Institute of Cancer Research
Frederic Davi
Frederic Davi Assistance Publique – Hôpitaux de Paris
Martin J. S. Dyer
Martin J. S. Dyer University of Leicester
Gunnar Juliusson
Gunnar Juliusson Lund University
Estella Matutes
Estella Matutes University of Barcelona
Nicholas Chiorazzi
Nicholas Chiorazzi Feinstein Institute for Medical Research

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Medicine in the USA opens doors to a range of online degrees and unique career pathways in healthcare. For those who wish to enter the workforce quickly, fastest lpn program options offer an accelerated route to practical nursing credentials, often in under a year.

Nursing professionals looking to specialize in mental health may consider the shortest pmhnp program, which can lead to lucrative and rewarding roles as psychiatric-mental health nurse practitioners.

Beyond clinical roles, an healthcare administration degree online can prepare you for management positions in hospitals, clinics, and other healthcare organizations, offering impressive career flexibility.

For those aiming higher, affordable online mha programs deliver advanced leadership skills without breaking the bank, positioning graduates for executive roles in healthcare management.

Exploring these related degrees is a strategic way to match your education to personal interests and growing job market needs within the U.S. healthcare industry.

Best Scientists Citing David Oscier

Trending Scientists

Recently Published Articles